Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of ceftobiprole versus vancomycin for complicated skin and skin structure infections
2004-001662-41Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2004
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftobiprole medocaril in skin and soft tissue infections (SSTIs) and Staphylococcosis (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Clinical outcome and Microbiological outcome. Started Oct 2004; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
skin and soft tissue infections (SSTIs)Staphylococcosis
Beyond the preview
Go deeper on 2004-001662-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001662-41.